Efficacy and safety of budesonide/formoterol pressurized metered-dose inhaler: Randomized controlled trial comparing once- and twice-daily dosing in patients with asthma

Allergy and Asthma Proceedings

Volumn 31, Issue 1, 2010, Pages 49-59

  Berger, William E ^a   Bleecker, Eugene R ^b   O'Dowd, Liza ^c   Miller, Christopher J ^c   Mezzanotte, William ^c  

^a Allergy & Asthma Associates of Northern California   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Asthma; Asthma control; Budesonide; Dosing regimen; Efficacy; Formoterol; Once daily dosing; Pressurized metered dose inhaler; Pulmonary function; Safety

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; PLACEBO; SALBUTAMOL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; BACKACHE; CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EMERGENCY CARE; EVENING DOSAGE; FEMALE; HEADACHE; HEART BUNDLE BRANCH BLOCK; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPETIGO; INFLUENZA; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; MORNING DOSAGE; MULTICENTER STUDY; MUSCULOSKELETAL CHEST PAIN; NOSE CONGESTION; PEAK EXPIRATORY FLOW; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SORE THROAT; SYMPTOMATOLOGY; THORAX PAIN; THRUSH; TRAFFIC ACCIDENT; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 76149101621     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2010.31.3309     Document Type: Article

References (15)

1. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma. National Asthma Education and Prevention Program Expert Panel Report 3, Full report 2007, Publication no. 08-4051. Available online at www. nhlbi.nih.gov/guidelines/asthma/asthgdln.htm; last accessed September 19, 2007.
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Revised 2006. Available online at www.ginasthma.org/Guidelineitem.asp??l1=2&l2=1&intId=60; last accessed May 29, 2007.
3. Chipps BE. Inhaled corticosteroid therapy for patients with persistent asthma: Learnings from studies of inhaled budesonide. Allergy Asthma Proc 30:217-228, 2009.
4. Mansfield LE. The future of the long-acting beta-adrenergic bronchodilators in the treatment of asthma. Allergy Asthma Proc 29:103-108, 2008.
5. Buhl R, Creemers JPHM, Vondra V, et al. Once-daily budesonide/ formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med 97:323-330, 2003.
6. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 136:225-244, 1987.
7. National Asthma Education and Prevention Program. Expert panel report: Guidelines for the diagnosis and management of asthma update on selected topics-2002. J Allergy Clin Immunol 110:S141-S219, 2002.
8. Juniper EF, Buist AS, Cox FM, et al. Validation of a standardized version of the asthma quality of life questionnaire. Chest 115:1265-1270, 1999.
9. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 47:81-87, 1994.
10. Masoli M, Williams M, Weatherall M, et al. The 24 h duration of bronchodilator action of the budesonide/formoterol combination inhaler. Respir Med 100:20-25, 2006.
11. Kerwin EM, Nathan RA, Meltzer EO, et al. Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily. Respir Med 102:495-504, 2008.
12. Palmqvist M, Persson G, Lazer L, et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: Onset of action, duration of effect and potency. Eur Respir J 10:2484-2489, 1997.
13. Corren J, Korenblat PE, Miller CJ, et al. Twelve-week randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adults and adolescents with asthma. Clin Ther 29:823- 843, 2007.
14. Noonan M, Rosenwasser LJ, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: A randomised clinical trial. Drugs 66:2235-2254, 2006.
15. Peters SP, Prenner BM, Mezzanotte WS, et al. Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients. Allergy Asthma Proc 29:499-516, 2008.